'김갑성' 기자의 전체기사
-
NABR: CITES Standing Committee Issues Assessment of Lon…
WASHINGTON, Nov. 20, 2025 -- The Standing Committee of CITES, an international body responsible for monitoring trade in animal species, announced the results of its review of animal breeding practices in Cambodia, thanking Cambodia for providing extensive data and relying on science. The report, released on Nov. 12, 2025 in advance of an upcoming Standing Committee meeting, is available at https://cites.org/eng/sc/79/agenda-documents. Among other positive findings, the report states that Cambodia has customs and inspection procedures in place that are "well-coordinated and
- 김갑성 기자
- 2025-11-20 01:33
-
BestQool Announces Up to 21% Off Red Light Therapy Devices…
NEW YORK, Nov. 19, 2025 -- This Black Friday, BestQool invites everyone to pause, breathe, and take a moment for themselves. Even a brief daily red light therapy session can help relax muscles, refresh the skin, and ease the day's tension. To make at-home wellness more accessible, BestQool is launching its official Black Friday promotion on Amazon. From 12:00 AM PST on November 20, 2025 to 11:59 PM PST on December 1, 2025, customers can enjoy: 20% off all BestQool products on Amazon, and an exclusive 21% discount on three of the brand's best-selling high-performance mode
- 김갑성 기자
- 2025-11-19 23:04
-
HKUST Commences Preparations for New Medical School
Inaugural Cohort in 2028, Cultivating Clinically Excellent and Technology-Savvy Doctors of the Future HONG KONG, Nov. 19, 2025 -- With the support of the HKSAR Government, The Hong Kong University of Science and Technology (HKUST) has commenced preparations to establish a new medical school. Dedicated to training a new generation of tech-savvy doctors, the School will bolster the future readiness of the local healthcare system and advance Hong Kong's development as an international hub for medical training, research, and innovation. Prof. Harry SHUM, HKUST Council Chairman, rema
- 김갑성 기자
- 2025-11-19 22:55
-
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-G…
BEIJING and LISBON, Portugal, Nov. 19, 2025 -- At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest accelerated protein and antibody services. The leading Chinese biotechnology company announced that its services can generate proteins in as little as 3 days and produce antibodies within 7 days, offering a potential step-change in speed for biopharma developers aiming to shorten drug discovery timelines worldwide. High-Speed Protein Production Across Six Expression Systems
- 김갑성 기자
- 2025-11-19 22:17
-
Nona Biosciences and Pfizer Announce Strategic Researc…
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications. Under the terms of the agreement, Pfizer will gain global rights to access Nona's proprietary HCAb platform
- 김갑성 기자
- 2025-11-19 20:08
-
Newton™ (Formerly Neurolens®) Partners with Hong Kong Opti…
DALLAS, Nov. 19, 2025 -- Newton™, Inc. (formerly Neurolens®), a leader in innovative eye care technology, today announced its expansion into Asian markets through a strategic partnership with Hong Kong Optical Lens Co Ltd (HKO) as the exclusive distributor for Hong Kong and China. This milestone in Newton's international growth brings the therapeutic solution of Neurolens for headaches, neck pain, and motion sickness, along with the everyday digital eye strain prevention of Sequel™ lenses, to millions across two of the world's most digitally connected markets. This
- 김갑성 기자
- 2025-11-19 19:00
-
KHB Highlights the Polaris V150 Automatic Chemiluminescence…
XI'AN, China, Nov. 19, 2025 -- Shanghai Kehua Bio-engineering Co., Ltd. (KHB), a global provider of in-vitro diagnostic (IVD) solutions, is showcasing its latest compact chemiluminescence platform—the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer—at MEDICA 2025, one of the world's leading medical industry exhibitions. As a featured product at this year's KHB booth, the Polaris V150 demonstrates the company's continuous innovation in automated diagnostics. Designed for small and medium-sized laboratories, as well as STAT and emergency testing in large hospitals a
- 김갑성 기자
- 2025-11-19 17:02
-
Rafa Laboratories Awarded up to $186 Million by BARDA to Deve…
JERUSALEM, Nov. 19, 2025 -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract
- 김갑성 기자
- 2025-11-19 13:01
-
Older Singaporeans Support Healthier SG, but Lifestyle Habits…
New SMU research reveals critical gaps in preventive health, lifestyle habits, and continuity of care as Singapore transitions into a super-aged society. Despite strong pro-health policies, everyday adoption - especially among older adults - remains limited. Bridging this gap requires environmental nudges that make healthy choices easier, more intuitive, and part of daily life. The upcoming symposium will explore these challenges and spotlight opportunities to strengthen pro-health behaviours. SINGAPORE, Nov. 19, 2025 -- A new study by the Singapore Management Uni
- 김갑성 기자
- 2025-11-19 12:30
-
Lynk Pharmaceuticals Announces Key Phase II Clinical Res…
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic dermatitis (AD). This randomized, double-blind, vehicle-controlled Phase II study evaluated the efficacy and safety of topical LNK01004 ointment (0.3% and 1.0%) in adult patients with moderate-to-severe AD. A total of 75 patients were enroll
- 김갑성 기자
- 2025-11-19 08:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-10_WED
- CNFINANCE ANNOUNCES THE RESULTS OF ITS EXTRAORDINARY GENERAL MEETING 19:15
- 資本の首都から、ADFWが資産運用の次なるフロンティアを描く 18:58
- 이제 유니온페이 카드로 15개 국가에서 애플 서비스 온라인 결제 가능 18:46
- World Gym Corporation (2762.TW) Reports Robust November Revenue Growth and Unveils Ambitious 2026 Strategic Roadmap 18:30
- Admission To Trading on The London Stock Exchange and Completion of Secondary Listing 18:27
- Under the Patronage of His Royal Highness the Crown Prince Governor of Riyadh Region Inaugurates MOMENTUM 2025 Development Finance Conference 17:57
- 엘프바•로스트마리, 2025년 획기적인 R&D 성과 및 새로운 안전 프로토콜 공개 17:22
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 10일 20시 40분